Metabolic & Cardiometabolic
statins decreases cardiovascular events in primary prevention
In plain terms: Do statins prevent cardiovascular events in people without established cardiovascular disease?
Strong support Metabolic & Cardiometabolic 💰 Industry COI noted
Part of: 💊 statins
RefutedContestedStrong support
consensus score 1.00
Yes, but with smaller absolute benefit: RCTs and meta-analyses show a real ~25-30% relative reduction in first events, though absolute risk reduction is modest in lower-risk populations.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
5 support 0 contradict 0 tested null 0 mixed · 5 sources, 5 independent groups · 3 superseded — pooled inside a review, counted once
The evidence (11)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Ridker et al. 2008 · N Engl J Med 2008 Nov 20;359(21):2195-2207 | RCT | supports | high | JUPITER: rosuvastatin in 17,802 with normal LDL but elevated hs-CRP cut major CV events 44% (HR 0.56); stopped early, robust but enriched-risk population. ↩ SUPERSEDED — pooled in the review above, counted once |
| Uthman 2025 · Health Technol Assess | meta-analysis | supports | high | Synopsis of a five-part NIHR evidence-synthesis programme in primary prevention. Its network meta-analysis (139 trials, 1,053,772 participants) reports 'statins (relative risk 0.81, 95% confidence interval 0.71 to 0.91) ... significantly reduced composite cardiovascular disease events and mortality', and its umbrella review of 95 systematic reviews reports that 'statins reduced cardiovascular disease mortality (relative risks 0.71-0.89), all-cause mortality (relative risks 0.66-0.93) and major cardiovascular disease events (relative risks 0.59-0.90)'. The article pools no new data of its own and summarises trials already represented by other statin meta-analyses in the vault, so it is review-layer corroboration, not an independent primary vote. The abstract does not single out statins as cost-effective; that finding is stated for primary-prevention interventions in aggregate. [Full-text CAL read: the abstract merges two networks — statins clear the EVENTS network (RR 0.81, 121 studies) but are absent from the significant interventions in the all-cause-MORTALITY network (102 studies), where BP lowering was the only significant class.] |
| Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, Ward K, Ebrahim S 2013 · Cochrane Database Syst Rev | meta-analysis | supports | moderate | Cochrane review of 18 RCTs (19 arms, 56,934 participants) in adults with no CVD history (<=10% prior CVD per trial): 'All-cause mortality was reduced by statins (OR 0.86, 95% CI 0.79 to 0.94); as was combined fatal and non-fatal CVD RR 0.75 (95% CI 0.70 to 0.81), combined fatal and non-fatal CHD events RR 0.73 (95% CI 0.67 to 0.80) and combined fatal and non-fatal stroke (RR 0.78, 95% CI 0.68 to 0.89).' Revascularisation RR 0.62 (0.54 to 0.72). 'There was no evidence of any serious harm caused by statin prescription.' Applicability limit: 'Fourteen trials recruited patients with specific conditions (raised lipids, diabetes, hypertension, microalbuminuria)', so the pooled population is risk-enriched rather than unselected. Read from the PubMed abstract only; the full review's risk-of-bias and GRADE tables were not available. |
| Mihaylova, Emberson, Blackwell, Keech, Simes, Barnes, Voysey, Gray, Collins, Baigent 2012 · Lancet 380(9841):581-590 | meta-analysis | supports | high | CTT IPD meta-analysis, 27 trials, n=174149, median 4.8y. In the two lowest 5-year-risk strata the proportional reduction per 1.0 mmol/L LDL was LARGER than average: RR 0.62 (99% CI 0.47-0.81) at <5% risk and 0.69 (0.60-0.79) at 5-<10%, vs RR 0.79 (95% CI 0.77-0.81) across all participants. Restricted to those with no history of vascular disease: RR 0.61 and 0.66; vascular mortality RR 0.85 (0.77-0.95) and all-cause mortality RR 0.91 (95% CI 0.85-0.97, p=0.007). Absolute benefit at <10% 5-year risk 'around 11 per 1000 over 5 years for each 1.0 mmol/L reduction in LDL cholesterol'; authors: 'This benefit greatly exceeds any known hazards of statin therapy.' |
| Sever ASCOT-LLA 2003 · Lancet 2003 Apr 5;361(9364):1149-58 | RCT | supports | high | ASCOT-LLA: 10,305 hypertensives aged 40-79 with at least three other cardiovascular risk factors and non-fasting total cholesterol <=6.5 mmol/L, randomised to atorvastatin 10 mg or placebo on top of randomised antihypertensive therapy; intention-to-treat. Pre-specified primary endpoint (non-fatal MI + fatal CHD): 100 vs 154 events, HR 0.64 (95% CI 0.50-0.83), p=0.0005 - a 36% relative reduction, emerging in the first year, with no significant heterogeneity across pre-specified subgroups. Secondary: fatal/non-fatal stroke 89 vs 121, 0.73 (0.56-0.96), p=0.024; total cardiovascular events 389 vs 486, 0.79 (0.69-0.90); total coronary events 178 vs 247, 0.71 (0.59-0.86). All-cause mortality was NOT significantly reduced: 185 vs 212, 0.87 (0.71-1.06), p=0.16. Total cholesterol fell about 1.3 mmol/L vs placebo at 12 months. Two qualifiers ride with this source: treatment was stopped after a median 3.3 years against a planned 5-year average (the abstract does not state the reason or the stopping rule, and truncated trials tend to overestimate effect), and 'primary prevention' here means high-risk primary prevention - every participant was hypertensive with 3+ additional risk factors - so it does not extend to low-risk populations. ↩ SUPERSEDED — pooled in the review above, counted once |
| Long, Liu, Cai J, Zhuang, Cai T, Zhou, Chai, Lin, Yang 2026 · Cardiovasc Drugs Ther | meta-analysis | supports | high | Systematic review + meta-analysis of RCTs in the exact claim population: 'Randomized controlled trials (RCTs) in adults without prior CVD that investigated statin treatment were included.' '25 RCTs (102,667 participants) were included. Compared to no statin treatment, statin treatment was associated with a reduced risk of MACE (RR, 0.73[95% CI, 0.67 to 0.80], P < 0.001), MI (RR, 0.68[95% CI, 0.60 to 0.77], P < 0.001), stroke (RR, 0.76[95% CI, 0.65 to 0.89], P = 0.001) and cardiovascular death (RR, 0.81[95% CI, 0.71 to 0.95], P = 0.008).' A meta-analysis of WITHIN-study subgroup differences found the benefit did not vary meaningfully by population: 'Statin therapy demonstrated consistent efficacy in CVD prevention across diverse populations, except that baseline lipid profiles and statin intensity may represent exploratory, hypothesis-generating signals of potential effect modification for stroke prevention, warranting further investigation.' Quality anchors: PROSPERO CRD42024579932, searches to 20 January 2026, 'Risk of bias was assessed using the Cochrane Risk of Bias tool.', public Chinese funding and 'Competing Interests: The authors declare no competing interests.' Limits: abstract-grade read (ahead-of-print, no OA full text), so I-squared and publication-bias results are unseen; the trial-level meta-regression signals are the authors' own exploratory caveat, not findings. Independence caveat: the pool includes WOSCOPS, ASCOT-LLA and JUPITER, which the vault also holds as standalone sources on this claim. |
| Kalra, Ray, Bajaj, Kushner, Wilcox, Dicklin, Kirkpatrick, Maki 2026 · J Clin Lipidol 2026;20(4):738-749 | meta-analysis | supports | high | Systematic meta-analysis of 14 primary-prevention cardiovascular outcomes trials (11 solely primary prevention, n = 74,466; 3 with >80% primary prevention, n = 24,071; 11 statin, 1 bempedoic acid, 1 ezetimibe, 1 statin+ezetimibe): 'In 13 trials, the pooled mean difference between groups in LDL-C reduction was 1.00 mmol/L (95% CI: 0.82-1.18 mmol/L) with a pooled estimate of 30% (relative risk: 0.70; 95% CI: 0.67-0.74) RRR for 4-point MACE per 1 mmol/L LDL-C reduction vs control.' Scope caveats: 3 of 14 trials are nonstatin, so this is an LDL-lowering rather than a pure statin estimate; the 4-point MACE composite includes coronary revascularization. The paper makes NO primary-vs-secondary-prevention comparison of its own - that contrast appears only in its Background as something CTT analyses 'have suggested'. Heavy author industry COI (four authors Midwest Biomedical Research; Ray and Maki hold lipid-drug consultancies); recorded, not tempered, because the pooled substrate is blinded adjudicated-outcome RCTs. Abstract-only read. |
| Tanaka, Fukumoto 2026 · Eur J Prev Cardiol | observational | supports | low | Narrative review, no new data and no systematic search: 'This review underscores the significance of statins for primary prevention in older adults.' The 26% figure is quoted from someone else's pooling - 'A meta-analysis revealed a 26% reduction in major vascular events per 1 mmol/L decrease in low-density lipoprotein cholesterol in older adults, with no heightened risks of cancer, haemorrhagic stroke, or cognitive decline.' - alongside PROSPER ('24% reduction in CAD mortality with statins, without notable cognitive or functional impairments') and EWTOPIA 75. The review concedes its own base: 'However, limited evidence exists regarding the efficacy of lipid-lowering therapy, particularly statins, for primary prevention in older populations,' with 'Ongoing STAREE and PREVENTABLE trials aim to provide further evidence.' Direction supports the claim; zero-weighted per CONVENTIONS section 5 because it restates studies rather than adding any. |
| Shepherd WOSCOPS 1995 · N Engl J Med | RCT | supports | high | WOSCOPS: pravastatin in 6,595 hypercholesterolemic men without prior MI cut nonfatal MI/coronary death 31% over ~5 years — first major primary-prevention statin trial. ↩ SUPERSEDED — pooled in the review above, counted once |
| Morsell B, Hamed M, Scwartz S, Martinez B, Roble K, Kahan J, Habib P 2026 · BMC Cardiovasc Disord | meta-analysis | supports | moderate | Meta-analysis of 10 RCTs (85,829 participants; 45,819 of them in the six statin-only trials) restricted to TRUE primary prevention - 'trials with any participants with prior CVD, vascular disease, or cerebrovascular events were excluded'. Statin-only sensitivity analysis: MACE '3.1% vs. 4.5%, RR 0.68, CI 95% 0.60-0.77, p < 0.001; I2 = 33', MI '1% vs. 1.7%, RR 0.60, 95% CI 0.51-0.70', revascularization RR 0.62 (0.51-0.75), stroke/TIA RR 0.68 (0.51-0.91); NNT 70 for statin-treated patients over a median 4.4 y. All-LLT pooled MACE RR 0.76 (0.68-0.84) but I2 = 66% with MACE defined differently in each trial. IMPORTANT COUNTERWEIGHT, same paper: its pre-registered PRIMARY outcome was null - 'LLTs did not reduce all-cause mortality compared with control (3.9% vs. 3.9%; RR 0.98, 95% CI 0.89-1.07) or cardiac mortality (1.4% vs. 1.5%; RR 0.92, 95% CI 0.82-1.04)' - so this source supports the EVENTS claim while finding no mortality benefit in the same population. Quality moderate not high: study-level pooling only ('our study was a study-level meta-analysis lacking patient-level analysis'), REDUCE-IT and FIELD contributed subgroup MACE data with no baseline characteristics, ALLHAT-LLT open-label, and the statin MACE subgroup is printed with an internally impossible p ('RR 0.68, 95% CI 0.60-0.77, p = 0.19') three sentences after the same estimate is given as p < 0.001. PROSPERO CRD42025606490; no external funding; no competing interests. |
| Fancher A, Lopez-Candales A, Sawalha K 2026 · J Lipid Atheroscler | observational | supports | low | Narrative review (no new data generated or analyzed). Its Table 1 tabulates three primary-prevention statin RCTs in the claim's direction: WOSCOPS (1995), '6,595 men, no known CHD, LDL ≥155 mg/dL', pravastatin 40 mg vs placebo — '31% risk reduction in primary outcome (RR, 0.69; 95% CI, 0.57–0.83'; ASCOT-LLA (2003), 10,305 hypertensive patients — '36% risk reduction in primary outcome (HR, 0.64; 95% CI, 0.50–0.83'; JUPITER (2008), 17,802 adults with LDL <130 mg/dL and CRP ≥2 mg/L — '44% risk reduction in MACE (HR, 0.56; 95% CI, 0.46–0.69'. The numbers are borrowed from those trials, not measured here, so this remains a zero-weight review appraisal. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.